Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NFZ5

UPID:
TNIP2_HUMAN

ALTERNATIVE NAMES:
A20-binding inhibitor of NF-kappa-B activation 2; Fetal liver LKB1-interacting protein

ALTERNATIVE UPACC:
Q8NFZ5; B1AKS4; B3KTY8; D3DVQ9; Q7L5L2; Q9BQR6; Q9H682

BACKGROUND:
The TNFAIP3-interacting protein 2, with alternative names such as A20-binding inhibitor of NF-kappa-B activation 2 and Fetal liver LKB1-interacting protein, is key in modulating NF-kappa-B activation. It prevents RIPK1 from interacting with NEMO/IKBKG and is crucial in the TLR4 and MEK/ERK signaling pathways, affecting innate immune responses. Its role extends to maintaining MAP3K8 stability and promoting endothelial survival, potentially acting as a transcriptional coactivator in the nucleus.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of TNFAIP3-interacting protein 2 holds promise for identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.